NCT01677624已完成3 期
A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 10
- 主要终点
- Success Rate of Embolization in the Target Vessel
研究概览
简要总结
To evaluate the efficacy and safety of transcatheter arterial embolization with E7040 in Japanese subjects with hypervascular tumor or arteriovenous malformation
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are subject to any of the following vascular embolization therapies
- •Subjects with hepatocellular carcinoma (HCC) who have deep stained early stage tumor confirmed by dynamic computerized tomography (CT) after bolus intravenous infusion of contrast media and have a typical finding of hypervascular tumor, and are not amenable to resection and local therapy, and meet any of the following (a) to (c).
- •1 lesion of >50 mm in diameter
- •2 or 3 lesions of >30 mm in at least one diameter
- •4 or more lesions
- •Metastatic hepatic cancer Subjects with metastatic hepatic cancer who have deep stained early stage tumor confirmed by dynamic CT after bolus intravenous infusion of contrast media and have a typical finding of hypervascular tumor but not amenable to resection, and whose primary lesion and extrahepatic lesion are controlled.
- •Hypervascular tumor other than metastatic hepatic cancer Subjects with deep stained early stage tumor confirmed by dynamic CT after bolus injection of contrast media and who have a typical finding of hypervascular tumor other than the liver (e.g., renal cell carcinoma, bone soft tissue sarcoma) and meets any of the following (a) to (b).
- •Subjects applicable to pre-operative arterial embolization therapy to reduce tumor size or volume of bleeding for safer conduct of surgical resection or local therapy (e.g., radiofrequency ablation (RFA))
- •Subjects in stable general condition and are applicable to pain control treatment
- •Arteriovenous malformation:
- •Subjects with arteriovenous malformation (except for central nervous system, heart, and lung) confirmed by dynamic CT but at a low risk of undesirable reflux into systemic circulation and with vessel malformation suitable for particle embolization in size
- •Subjects with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 (PS 0-1 for metastatic hepatic cancer)
- •No carry-over effect of prior therapy or adverse drug reactions which may influence the embolic effect of E7040, if having a history of prior therapy time elapsed from the end of prior therapy to the start of E7040 embolization therapy should be: Surgery: greater than or equal to 6 weeks Local therapy: greater than or equal to 4 weeks Embolization for non-target vessel: greater than or equal to 4 weeks
- •With a survival of greater than or equal to 12 months after the prior arterial embolization therapy using E7040
排除标准
- •Subjects with clinical symptom or brain metastasis or cerebral encephalopathy requiring medical treatment
- •Suspected to have hepatocellular carcinoma (HCC) judging from clinical findings in patients with any disease other than HCC
- •Previously treated with arterial embolization therapy in target vessel
- •Previously treated with arterial embolization therapy in non-target vessel, resection in target organ, or local therapy (e.g., RFA) (except for HCC patient)
- •Subjects expected to have artery-pulmonary vein shunt or right-to-left shunt, or those with a possible risk of influx of embolized particles into the central nervous system.
研究组 & 干预措施
E7040
Experimental
干预措施: E7040 (Device)
结局指标
主要结局
Success Rate of Embolization in the Target Vessel
时间窗: Day 1 (embolization) up to Day 30 after treatment
Embolization performance was graded per 1 of 4 levels: (1) complete embolization, 100% disappearance of contrast enhancement in the target vessel as evaluated by post-embolization digital subtraction angiography; (2) intensive embolization, ≥80% disappearance; (3) moderate embolization, ≥50% and \<80% disappearance; (4) mild embolization, \<50% disappearance. Success rate was obtained by calculating the percentage of complete embolization and intensive embolization cases. Embolization performance evaluated by both the Imaging Evaluation Committee and by the Investigator or Subinvestigator.
次要结局
- Success Rate for Operability of Embolization(Day 1 (embolization) up to Day 30 after treatment)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
Randomized Controlled Trial of Endovascular Therapy for Acute Large Vessel Occlusion With Large Ischemic CoreMechanical ThrombectomyLarge Ischemic CoreNCT03702413Hyogo Medical University203
进行中（未招募）
2 期
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion DependenceMyelodysplastic SyndromesNCT04797000Novartis Pharmaceuticals36
招募中
不适用
Exploratory Clinical Trial of EPI-743 in Japanese MELAS Syndrome PatientsMELAS: mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodesJPRN-UMIN000010783ational Center of Neurology and Psychiatry, Japan10
已完成
3 期
PROMUS Element Japan Small Vessel TrialCoronary Artery DiseaseAtherosclerosisNCT01080261Boston Scientific Corporation60
已完成
3 期
Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD AloneDiabetes Mellitus, Type 2DiabetesNCT01512108Novo Nordisk A/S363